![](https://www.huntingtonsociety.ca/wp-content/uploads/2014/08/Break-News_Genetics-Landing-Header.jpg)
The first few patients have received doses of an experimental RNA-targeting drug for Huntington’s disease, it was announced today.
The trial aims to test the safety of an experimental drug known as ISIS-HTTRx, discovered and developed by Isis Pharmaceuticals.